To Assess the Safety and Effectiveness of X-Ice Talcum Powder in relieving the Skin Itching, Heat Rash, Burning, Minor Infections, and Body Odor

A prospective single-arm clinical trial to assess the safety and efficacy of X-Ice talcum powder in providing relief from skin itching, treating heat rash, burning sensation, minor skin infections, and curing body odor. - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/076933

Enrollment

Registered

2024-11-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified Health Condition 2: L598- Other specified disorders of the skin and subcutaneous tissue related to radiation Health Condition 3: L599- Disorder of the skin and subcutaneous tissue related to radiation, unspecified Health Condition 4: L089- Local infection of the skin and subcutaneous tissue, unspecified Health Condition 5: R61- Generalized hyperhidrosis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female aged 18-65 years. 2. Presenting with symptoms of prickly heat, heat rash, burning sensation, minor skin infections, or body odor. 3. Able to provide written informed consent. 4. Willing to comply with the study protocol and visit schedule.

Exclusion criteria

Exclusion criteria: 1. Known allergy or hypersensitivity to talcum powder or any of its components. 2. Presence of severe skin conditions requiring systemic treatment. 3. Use of other topical treatments for skin conditions during the study period. 4. Pregnant or breastfeeding women. 5. Participation in another clinical trial within the last 30 days.

Design outcomes

Primary

Measure	Time frame
Proportion of subjects achieving at least a 50% reduction in itching, heat rash, burning sensation, minor skin infections, and body odor by Week 4.Timepoint: Day 1, Day 7, Day 14, and Day 28	—

Secondary

Measure	Time frame
Time to onset of symptom relief. Patient-reported outcomes using a standardized questionnaire (Visual Analog Scale for itching, rash severity, burning sensation, and overall satisfaction).Timepoint: Day 1, Day 7, Day 14, and Day 28	—

Countries

India

Contacts

Public ContactMs Arpita Malgi

Samahitha Research Solutions

satyalm@samahitha.com9739001749

Outcome results